Full Recovery of a Child with Fulminant Myocarditis after Levosimendan Therapy

Background: Fulminant myocarditis is a rare, life-threatening condition. Decompensated heart failure caused by fulminant myocarditis is managed with inotropic agents, mechanical ventilation, and mechanical circulatory support. Levosimendan is a novel inotropic agent that also has vasodilatory and ca...

Full description

Saved in:
Bibliographic Details
Published inErciyes Medical Journal Vol. 43; no. 5; p. 505
Main Authors Argun, Mustafa, Sinmez, Isin, Samsa, Hasan, Yilmaz, Onur, Yilmaz, Mustafa
Format Journal Article
LanguageEnglish
Published Istanbul KARE Publishing 01.09.2021
Kare Publishing
Subjects
Cardiovascular agents
Case studies
Causes of
Diagnosis
Dosage and administration
Drug therapy
Heart failure
Myocarditis
Pediatric research
Turkey
Online AccessGet full text

Cover

More Information
Summary:Background: Fulminant myocarditis is a rare, life-threatening condition. Decompensated heart failure caused by fulminant myocarditis is managed with inotropic agents, mechanical ventilation, and mechanical circulatory support. Levosimendan is a novel inotropic agent that also has vasodilatory and cardioprotective properties. However, information about levosimendan use in children is limited in the literature. Case Report: We report the full recovery of a 3.5-year-old male patient with an inotrope-resistant heart failure treated with levosimendan therapy who was diagnosed as having fulminant myocarditis after presenting with acute decompensated heart failure and low cardiac output. Conclusion: Levosimendan therapy may offer an effective treatment for children with acute decompensated heart failure secondary to fulminant myocarditis resistant to standard therapy. Keywords: Fulminant myocarditis, levosimendan, child
ISSN:2149-2247
2980-2156
DOI:10.14744/etd.2020.87513